Non-AI equities such as Johnson & Johnson could be hurt if more than $10T of AI capex by decade's end triggers a sovereign debt crisis, with hyperscaler borrowing pushing up interest rates, bankrupting countries with little AI exposure and crashing non-AI stocks. AI capex is a bit over $1 trillion this year and should top $2 trillion by 2028, with OpenAI and Anthropic taking a growing share as they monetize compute better and outbid everyone else. dwarkesh.com 

Johnson & Johnson's valuation does not make sense at a premium to Thermo Fisher and roughly flat to Danaher. @PythiaR, replying, calls J&J a clean story with limited patent-loss risk until the 2030s and a strong pipeline, but expensive at 22x, and prefers medtech such as Stryker. Pharma may simply have been easier to own than medtech given OBBB payer eligibility changes and hospital procedure volume risk, while life sciences has disappointed. x.com 

Johnson & Johnson is not the S&P 500 laggard its five-year sideways chart suggests once dividends and longer timelines are counted: over 20 years it trails the index by only the tiniest amount. That says something for a very low-beta stock with one of only two AAA credit ratings, alongside Microsoft. It is a strong anchor for when momentum and growth stocks get clobbered. x.com  x.com  x.com 

Protagonist is a really low-risk story because even a J&J buyout, its worst case, would yield a fast profit. It is not the most exciting story since big pharma gets 90% of revenues. The best case is ongoing royalties funding heavy buybacks that shrink the float over time. Keeping IL-17 and other early drugs for shareholders would be an extra stroke of luck. x.com 

Stryker's rare double miss looks like quarterly noise, since full-year 2026 guidance is unchanged. Healthcare stocks are widely hated after five years of broken charts from the COVID boom-bust, but fundamentals say otherwise. They are the ultimate safety stocks, and the time to buy them is when no one wants them. x.com 

Stryker is a slow-and-steady compounder, leading knee and hip replacement as an aging population spends more on care. People over 65 spend 3x more on healthcare, and baby boomers are turning 65. A three-year FDA head start let Stryker install over 3,000 Mako robots, past 2 million procedures, locking in surgeons and hospitals. Each system drives recurring implant, disposable, software and service revenue AI cannot code away. Sales grow mid-teens, 4% above peers. x.com 

Q1 medical device fears are overblown, a positive for small- and mid-cap device makers such as AngioDynamics. Johnson & Johnson's medical device trends look like normal seasonality. Boston Scientific, by contrast, now looks like a poor company. x.com 

Stryker's 10% post-earnings drop is unwarranted because the numbers were fine. Organic revenue was in line, margins beat, full-year guidance was reiterated and MedSurg is tracking to the high end of its range. Keeping guidance after a cyber incident, despite end-market callouts from Intuitive Surgical and HCA, should be positive. The stock is at its lowest multiple since 2015, derated from over 30x to 18x, with Mako and neurovascular strong; a collapse in hospital buying is the risk. x.com  x.com 

Stryker's soft summer reflects a deteriorating company, not macro weakness. No other device company talked about a soft summer, yet the market reads it as a macro issue and people want to buy Stryker, using it to express a preconceived thematic trade. The macro is fine; Stryker is the problem. x.com  x.com 

AbbVie's terminal value is a concern: it has had big autoimmune hits to backfill Humira, yet it still trades at 19x forward earnings on a $450B market cap, while Johnson & Johnson's 2024-25 acquisition spree is paying off. x.com